1.02Open1.20Pre Close3 Volume833 Open Interest7.50Strike Price304.00Turnover192.57%IV13.33%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry1.00Extrinsic Value100Contract SizeAmericanOptions Type-0.4281Delta0.1476Gamma7.14Leverage Ratio-0.0426Theta-0.0013Rho-3.06Eff Leverage0.0054Vega
Vir Biotechnology Stock Discussion
US FDA: Revoked Emergency Use Authorization for GSK and Vir Biotechnology's Sotrovimab as of Dec 13 - Website
*************************************
REVERSE...
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA Prime Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
📊⚡️📊
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
📊⚡️📊
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Phase 3 Eclipse Program to Evaluate Tobevibart and Elebsiran
No comment yet